Global Spinal Muscular Atrophy Treatment Market (2019-2023): The Rising Number of Initiatives Being Taken by Organizations to Provide Patient Care is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 20, 2018--The “Global Spinal Muscular Atrophy Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The spinal muscular atrophy treatment market is projected to register a CAGR of almost 23% by 2023. With the increase in development of new innovative therapies, there is a growing demand for spinal muscular atrophy treatment.
The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials.
The first therapy employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh copy of the gene. The second therapy, which has already been approved by the FDA, is called nusinersen (SPINRAZA). It promotes the production of the nerve protein by SMN2.
These two therapies have improved the motor function in babies. AveXis in 2018, entered into a licensing agreement with Genethon for the in vivo gene therapy delivery of AAV9 vector into the CNS for the treatment of spinal muscular atrophy.
According to the report, one driver influencing this market is the rising number of initiatives being taken by organizations to provide patient care. Several organizations are taking initiatives to provide the best care to patients suffering from spinal muscular atrophy, and some organizations such as Cure SMA are offering care packages and family support staff to newly diagnosed patients.
Further, the report states that one challenge affecting this market is the low adoption of spinal muscular atrophy treatment. One of the major challenges faced in the market is low adoption of spinal muscular atrophy drug therapy as patients have a higher propensity towards other approaches, such as physiotherapy, nutritional support, respiratory care, and enablement strategies.
The market appears to be highly concentrated and with the presence of Biogen, the market is expected to grow less concentrated with the emergence of new players during the forecast period. Factors such as increase in development of new innovative therapies and rising number of initiatives being taken by organizations to provide patient care, will provide considerable growth opportunities to spinal muscular atrophy treatment companies. Biogen is the major company covered in this report.
Key Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSISPipeline analysis
PART 05: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 07: MARKET SEGMENTATION BY TYPEMarket segmentation by type Comparison by type Type 2 - Market size and forecast 2018-2023 Type 3 - Market size and forecast 2018-2023 Type 1 - Market size and forecast 2018-2023 Type 4 - Market size and forecast 2018-2023 Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TREATMENTSegmentation by treatment
PART 10: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGESMarket drivers Market challenges
PART 13: MARKET TRENDSRising awareness of treatment and diagnosis of spinal muscular atrophy Development of new innovative therapies for treatment Advances in diagnostic techniques
PART 14: VENDOR LANDSCAPEOverview Landscape disruption
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Biogen
For more information about this report visit https://www.researchandmarkets.com/research/gl3nvb/global_spinal?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005260/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/20/2018 04:48 AM/DISC: 11/20/2018 04:48 AM